Generic Name and Formulations:
Mexiletine HCl 150mg, 200mg, 250mg; caps.
Various generic manufacturers
Indications for Mexiletine:
Documented life-threatening ventricular arrhythmias.
Take with food or antacid. Initially 200mg every 8hrs. Adjust dose if needed at not less than 2–3 day intervals in 50–100mg increments. Usual dose: 200–300mg every 8hrs; max 1.2g/day. If arrhythmia is controlled by ≤300mg every 8hrs, may try dividing same daily dose every 12hrs; max 450mg every 12hrs. See literature for information on rapid induction and changing from other antiarrhythmics.
Cardiogenic shock. 2nd- or 3rd- degree AV block unless paced.
Hepatic impairment. Severe heart failure. Sinus node dysfunction or intraventricular conduction defects. Hypotension. Epilepsy. Monitor ECG, blood and liver function. Pregnancy (Cat.C). Nursing mothers: not recommended.
Class IB antiarrhythmic.
May potentiate other antiarrhythmics, theophylline. Monitor control if used with hepatic enzyme-inducing drugs. Avoid drugs or diets that alter urinary pH.
GI upset, dizziness, tremor, nervousness, ataxia, chest pain, blurred vision, exacerbated arrhythmias, hepatotoxicity.
Formerly known under the brand name Mexitil.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes In on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma